A European screening programme for familial hypercholesterolaemia: a call to action
- PMID: 36718096
- DOI: 10.1093/eurjpc/zwad018
A European screening programme for familial hypercholesterolaemia: a call to action
Conflict of interest statement
Conflict of interest: S.G.: Lecture honoraria from Boehringer Ingelheim, Daiichi Sankyo, Cardinal Health, AMGEN, Bayer, AstraZeneca, Abbott; Advisory Board Membership: Bayer AG, Boehringer Ingelheim, Abbott, Siemens Healthineers. O.W.: Lecture honoraria and travel support from AMGEN, Daiichi-Sankyo, Amarin, Novo Nordisk, Novartis, Hexal GmbH, Sanof-Aventis, Fresenius, Akcea Therapeutics, TAD Pharma, and the German Cardiac Society (DGK). Advisory Board Membership: AMGEN, Sanofi-Aventis, Novartis, Daiichi-Sankyo, Hexal GmbH, Akcea Therapeutics, and Pfizer.
Comment on
-
Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations.Eur J Prev Cardiol. 2022 Dec 21;29(18):2301-2311. doi: 10.1093/eurjpc/zwac200. Eur J Prev Cardiol. 2022. PMID: 36059237
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
